H.U. Group Holdings,Inc. Q2 FY2026 earnings call

Overall Financial Performance

• All three segments achieved year-over-year revenue growth, with consolidated EBITDA and operating profit also growing year-over-year. Consolidated operating profit for the first half reached 2.33 billion yen, up 1.37 billion yen year-over-year; excluding M&A-related costs, core operating hit approximately 2.8 billion yen. Operating profit was slightly weaker than planned in Q2, but first half performance remained within expected ranges.
• Recurring profit and net income returned to positive territory, driven by higher operating profit; first half net income reached 210 million yen. A special gain from the Carelux share transfer and fixed asset sales will be booked in Q3, putting full year net income of 7 billion yen within reach.
• Free cash flow hit 4.2 billion yen, up sharply year-over-year, as disciplined investment selection offset stable operating cash flow; net interest-bearing debt declined, in line with the start-of-year plan.

Strategic and Operational Updates

• NEURO Global Expansion: Following US FDA approval, the company plans to submit approval applications in Japan and Europe by the end of 2025. It is also preparing expansion into India, China, South America, the Middle East, and other Asian markets for long-term growth. Domestic market entry has already begun with research use testing prior to formal approval, and the company is expanding beyond Alzheimer's testing to target the broader neurological disease space by leveraging ADx NeuroSciences capabilities to strengthen the NEURO pipeline.
• Capital Allocation Optimization: The company signed a share transfer agreement for Carelex, a welfare equipment rental wholesale business, as part of its mid-term plan to improve capital efficiency. Closing is scheduled for December 1, 2025, after which Carelex will become an equity method investee, with full share transfer planned 18-24 months later. The HS segment will now refocus on sterilization/surgery and home healthcare businesses.
• LTS Operational Improvement: Price optimization (price increases) are nearly complete, with most of the annual impact already visible. Fixed cost cutting initiatives are slightly behind plan, but the company expects to catch up in the second half. IT system migration issues are expected to stabilize by Q3, eliminating related emergency costs by Q4.

1. LTS Segment: Revenue grew driven by strong demand for genetic and specialized testing, achieved net year-over-year operating profit growth after absorbing higher H.U. Bioness Complex related costs (depreciation and running costs). Q2 2025 operating profit was nearly break-even, in line with plan. For the first half, margin improvement initiatives (pricing and service level optimization, partially offsetting input cost increases) delivered 1.45 billion yen in incremental profit. Fixed cost increases from Bioness Complex were partially offset by headcount and outsourcing cost cuts, resulting in a net 220 million yen fixed cost increase year-over-year.
2. IVD Segment: NEURO-related revenue reached 4.1 billion yen, up 2.2x year-over-year, driven by post-FDA approval adoption at major US testing centers. CDMO revenue grew 5% excluding foreign exchange impact, even with headwinds from the weak Chinese market, after including the June 2025 acquisition of PSG. The segment saw a year-over-year operating profit decline, driven by M&A-related costs, foreign exchange headwinds, and temporary product mix shifts; excluding these one-time impacts, core business profit remained nearly flat year-over-year. NEURO growth offset a 1.4 billion yen decline in COVID-19 related revenue, leaving domestic Lumipulse core revenue flat year-over-year.
3. HS Segment: Revenue and operating profit grew year-over-year, driven by steady growth in sterilization and surgery-related businesses, plus a contribution from Gaia Medicare, which was consolidated in December 2024. Pricing optimization also supported profit growth.

• Full year consolidated net income guidance of 7 billion yen is maintained, supported by the planned special gain from the Carelex share transfer in Q3.
• LTS segment: Management maintains its target of achieving the start-of-year full year profit level, driven by sales growth, steady margin expansion, and expected catch-up on fixed cost cutting in the second half. Some upside to full year results is possible from stronger than expected sales growth.
• IVD segment: Management maintains its target of 11.5 billion yen full year operating profit, with NEURO expected to drive ongoing growth in the second half to offset ongoing Chinese market headwinds in CDMO.
• All first half performance is within the range of original full year plans, with no overall guidance revisions announced.

• Weak macro conditions in the Chinese market are weighing on CDMO segment results, and no quick recovery is expected in the second half of 2025, creating downside risk to IVD segment profit.
• LTS segment fixed cost reduction initiatives (for H.U. Bioness Complex related cost increases) are slightly behind plan, creating short-term pressure on profit if catch-up efforts do not deliver expected savings.
• Price increase impacts for LTS are slightly lower than originally forecast, though management notes this gap has been offset by other cost control measures.
• BMGL, an equity method investment, has expanded investment in sales and marketing to capture growth in the US pediatric and rare disease whole genome sequencing market, leading to higher than expected equity method losses in the first half. A planned 32 million USD loan repayment was delayed, keeping full year losses slightly above original projections.
• LTS Q2 operating profit missed the break-even target, coming in at a 100 million yen deficit due to higher running costs and IT system issue response costs, though management expects this gap to be recovered in the second half.

Q: Why did the company change its disclosure method for H.U. Bioness Complex related costs? What is the breakdown of the 200 million yen year-over-year fixed cost increase, and why are cost cutting measures delayed? / A: The new disclosure framework follows up on the 3-factor (sales growth, margin expansion, fixed cost reduction) breakdown of LTS profit improvement shared in the May 2025 plan update. While Bioness Complex added a total of 1.6 billion yen in annualized fixed cost (including depreciation) year-over-year, cost cutting measures have reduced this net increase to 220 million yen. There is no single specific cause for the delay; all cost cutting initiatives are slightly behind schedule, and management will prioritize catching up in the second half.

Q: What caused the LTS segment Q2 deficit after a Q1 profit, and when will price increase impacts fully materialize? What additional non-organic growth drivers are there for the second half? / A: Q2 was originally guided to be near break-even, and a 100 million yen deficit resulted from unexpected higher running costs and IT system migration issue response costs; this deficit will be recovered in the second half, with Q3 expected to return to profit. Over 90% of contract renewals for price increases are already complete, so the full impact will mostly be seen in the second half, with only limited additional impact coming later. IT system issues are expected to stabilize in Q3, eliminating related emergency costs from Q4 onward, and fixed cost cutting will continue steadily to deliver incremental profit.

Q: Why has IVD profit not grown faster despite the strong NEURO growth? Is Chinese market weakness a major downside risk for the second half? / A: NEURO growth has been offset by two headwinds: the Chinese CDMO market has been much weaker than expected, which weighed on results, and domestic Lumipulse core revenue also came in slightly below plan. Excluding 470 million yen in M&A-related costs, these headwinds explain the flat core profit result. China is not a large enough share of overall CDMO revenue to create material full year risk; management expects Chinese weakness to persist into next year but counts on growth in other regions to offset it, and NEURO growth will still allow IVD to hit its full year profit target.

Q: Has the contraction of the clinic customer segment in LTS mostly concluded, and is there room for additional price increases next year? / A: The number of clinic customers has declined through the first half, and the contraction is now mostly complete. The company is continuing to implement pricing optimization for the clinic business alongside broader portfolio adjustments. Management did not commit to future price increases, noting ongoing focus on margin improvement through operational efficiency rather than relying on further price changes.